Table 1.
Patient baseline demographic and clinical characteristics.
| LeToHAIC group (n = 71) | Lenvatinib group (n = 86) | p-value | |
|---|---|---|---|
| Sex | 0.24 | ||
| Male | 59 | 77 | |
| Female | 12 | 9 | |
| Age, years | 0.35 | ||
| ⩽50 | 40 | 42 | |
| >50 | 31 | 44 | |
| ECOG | 0.38 | ||
| 0 | 14 | 22 | |
| 1 | 57 | 64 | |
| HBsAg | 0.5 | ||
| Positive | 62 | 78 | |
| Negative | 9 | 8 | |
| AFP, ng/ml | 0.98 | ||
| ⩽400 | 26 | 31 | |
| >400 | 45 | 55 | |
| DCP, mAU/ml | 0.91 | ||
| ⩽10,000 | 32 | 38 | |
| >10,000 | 39 | 48 | |
| ALBI grade | 0.43 | ||
| 1 | 31 | 43 | |
| 2 | 40 | 43 | |
| Albumin, g/l | 0.45 | ||
| <40 | 37 | 50 | |
| ⩾40 | 34 | 36 | |
| Total bilirubin, μmol/l | 0.35 | ||
| ⩽20 | 55 | 61 | |
| >20 | 16 | 25 | |
| ALT, U/l | 0.47 | ||
| ⩽50 | 33 | 35 | |
| >50 | 38 | 51 | |
| AST, U/l | 0.35 | ||
| ⩽60 | 23 | 34 | |
| >60 | 48 | 52 | |
| Tumor size, cm | 0.21 | ||
| ⩽10 | 26 | 40 | |
| >10 | 45 | 46 | |
| Tumor number | 0.14 | ||
| ⩽3 | 3 | 9 | |
| >3 | 68 | 77 | |
| PVTT | 0.44 | ||
| Absent | 16 | 24 | |
| Present | 55 | 62 | |
| HVTT | 0.82 | ||
| Absent | 45 | 53 | |
| Present | 26 | 33 | |
| Metastasis | 0.35 | ||
| Absent | 55 | 61 | |
| Present | 16 | 25 |
Calculated using the following equation: linear predictor = (log10 bilirubin μmol/l × 0.66) + (albumin g/L × −0.085). The continuous linear predictor was further categorized into three different grades for prognostic stratification purposes: grade 1 (less than −2.60), grade 2 (between −2.60 and −1.39) and grade 3 (above −1.39).
Statistical significance was assessed with the Chi-square test.
AFP, α-fetoprotein; ALBI, albumin-bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DCP, des-γ-carboxy prothrombin; ECOG, Eastern Cooperative Oncology Group; HBsAg, hepatitis B surface antigen; HVTT, hepatic vein tumor thrombus; PVTT, portal vein tumor thrombus.